Arovella Therapeutics Limited (AU:ALA) has released an update.
Arovella Therapeutics Limited, an innovative biotech firm, has announced the issuance of 400,000 ordinary shares without public disclosure, in compliance with the Corporations Act. The company specializes in developing cell therapy platforms to treat blood cancers and solid tumors, including their lead product ALA-101, which targets specific cancer antigens. Arovella is also advancing its technology for solid tumor treatments through licensing and new program incorporations.
For further insights into AU:ALA stock, check out TipRanks’ Stock Analysis page.
